Project Title: eRAPID Towards safer delivery and monitoring of cancer treatments. Electronic patient self-Reporting of Adverse-events (AE): Patient Information and aDvice
Project Start Date: January 2013
Anticipated End Date: March 2019
Aims and Objectives
eRAPID is a 5 year multi-centre research programme funded by the National Institute for Health Research (NIHR). The research will be carried out in three hospital sites; Leeds, Bristol and Manchester. During the programme a new online system to improve the monitoring and management of symptoms and side effects related to cancer treatment (chemotherapy, radiotherapy and surgery) will be evaluated. The online reports are immediately displayed in the patient hospital electronic records, so clinicians can use them to improve and streamline patient care. This is a truly unique feature of the eRAPID system. The aim of eRAPID is to improve the safe delivery of cancer treatment, enhance the patient experience and care and to standardise documentation of symptoms and side effects of treatments.
Background and rationale
Over 250,000 patients in the UK are diagnosed with cancer each year. All cancer treatments have acute and long-term Adverse Effects. An estimated 1.8 million people are living with and beyond cancer. Improving AE reporting/ documentation during and after cancer treatment can improve patient care through earlier detection/timely management of AE, directing patients to appropriate services for late-radiotherapy effects and supporting patients post-discharge after cancer surgery. However, a feasible, cost-effective and sustainable model is required. Information technology offers potential solutions for remote-monitoring, but there is a need for applied research to develop and evaluate such approach.
The programme of work will develop and test the eRAPID intervention in:
- systemic treatment (chemotherapy and targeted therapies)
- radiotherapy for pelvic malignancies
- surgery for upper gastro-intestinal cancer
The programme is organised in 5 work-packages (WP) applied across the clinical areas Work-packages 1 to 3 comprise the development of eRAPID intervention.
WP1 Electronic platform. Implement a secure flexible electronic platform for patients to report AE from clinic and home, with real-time AE documentation in Electronic-Patient-Records.
WP2 Patients: AE items and advice. Develop patient-reported AE items, with defined severity grades and evidence-based patient advice and alerts.
WP3 Professionals and care pathways. Understand and map the current patient pathways aiming to integrate eRAPID and identify key professionals to be trained in its delivery.
On completion of the above, the eRAPID intervention model will be developed, ready for testing.
WP4 Feasibility and pilot studies. Pilot eRAPID assessing patient /clinician feasibility and acceptability.
WP5 Large Scale Evaluation: Undertake a randomised controlled trial to establish clinical and cost-effectiveness of eRAPID in Systemic-Treatment.
The Research Team
The programme brings together senior researchers, clinicians and patients with expertise and strong track records in cancer care, patient-centred research (development/validation of Patient-Reported-Outcome-Measures), health informatics, applications of IT for patient self-reporting, clinical trials methodology, health economics, qualitative methods and implementing interventions.
Leeds, Bristol and Manchester offer an internationally recognised environment for conducting applied health-services and clinical research. We have received excellent support from clinical leads in the 3 centres, from the Yorkshire Cancer Research Network and the West Yorkshire Comprehensive Local Research Network.
Lead applicant: Galina Velikova (Medical Oncology and Patient-Reported Outcomes)
- Julia Brown (Clinical Trials, Leeds)
- Jenny Hewison (Health Services Research, Leeds)
- Claire Hulme (Health Economics, Leeds)
- Barbara Potrata (Qualitative research)
- Richard Jones (Health Informatics, Leeds)
- Jane Blazeby (Surgical Oncology, Bristol)
- Kevin Franks (Clinical Oncology & Radiotherapy, Leeds)
- Geoff Hall (Medical Oncology, Cancer Lead Clinician and IT, Leeds)
- Martin Waugh (Health Informatics, PPM, Leeds)
- Foluke Ajayi (NHS Manager for Oncology, Leeds)
- Clare Harley (Patient-Reported Outcomes, Leeds)
- Peter Selby (Medical Oncology, Leeds; Association of Cancer Physicians)
- Susan Davidson (Clinical Oncology, Manchester)
- Krystina Kozlowska (Lead Cancer Nurse, Leeds)
- Carolyn Morris- Patient representative
eRAPID represents independent research funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research Programme (Grant Reference Number RP-PG-0611-20008).
Public Launch Presentation 4th February 2013